BR9907647A - Composições contendo composto orgânicos - Google Patents

Composições contendo composto orgânicos

Info

Publication number
BR9907647A
BR9907647A BR9907647-0A BR9907647A BR9907647A BR 9907647 A BR9907647 A BR 9907647A BR 9907647 A BR9907647 A BR 9907647A BR 9907647 A BR9907647 A BR 9907647A
Authority
BR
Brazil
Prior art keywords
organic compounds
compositions containing
containing organic
epothilone
infusion
Prior art date
Application number
BR9907647-0A
Other languages
English (en)
Other versions
BR9907647B1 (pt
Inventor
Peter Van Hoogevest
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26313062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9907647(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9802451.6A external-priority patent/GB9802451D0/en
Priority claimed from GBGB9813646.8A external-priority patent/GB9813646D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR9907647A publication Critical patent/BR9907647A/pt
Publication of BR9907647B1 publication Critical patent/BR9907647B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçõES CONTENDO COMPOSTOS ORGâNICOS"<D>. Formulações farmacêuticas que compreendem uma epotilona na forma de um concentrado para infusão ou uma composição liofilizada e processos de administração de uma epotilona na forma adequada para administração parenteral.
BRPI9907647-0A 1998-02-05 1999-02-03 Formulação farmacêutica na forma de um concentrado para infusão, o qual deve ser diluído antes da administração, e solução para infusão BR9907647B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9802451.6A GB9802451D0 (en) 1998-02-05 1998-02-05 Organic compounds
GBGB9813646.8A GB9813646D0 (en) 1998-06-24 1998-06-24 Organic compounds
GB9802451.6 1998-06-24
GB9813646.8 1998-06-24
PCT/EP1999/000702 WO1999039694A2 (en) 1998-02-05 1999-02-03 Compositions containing organic compounds

Publications (2)

Publication Number Publication Date
BR9907647A true BR9907647A (pt) 2000-11-14
BR9907647B1 BR9907647B1 (pt) 2014-04-01

Family

ID=26313062

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9907647-0A BR9907647B1 (pt) 1998-02-05 1999-02-03 Formulação farmacêutica na forma de um concentrado para infusão, o qual deve ser diluído antes da administração, e solução para infusão

Country Status (37)

Country Link
US (5) US20030203876A1 (pt)
EP (1) EP1052974B1 (pt)
JP (2) JP4644364B2 (pt)
KR (3) KR100669174B1 (pt)
CN (2) CN1623543A (pt)
AR (1) AR017979A1 (pt)
AT (1) ATE431733T1 (pt)
AU (1) AU753519B2 (pt)
BE (1) BE1012140A3 (pt)
BR (1) BR9907647B1 (pt)
CA (1) CA2320182C (pt)
CL (1) CL2003002786A1 (pt)
CO (1) CO4920246A1 (pt)
CY (1) CY1109311T1 (pt)
CZ (1) CZ303168B6 (pt)
DE (1) DE69940904D1 (pt)
DK (1) DK1052974T3 (pt)
ES (1) ES2324378T3 (pt)
FR (1) FR2774909B1 (pt)
HK (1) HK1033809A1 (pt)
HU (1) HUP0101564A3 (pt)
ID (1) ID26549A (pt)
IL (2) IL137550A0 (pt)
IT (1) IT1313549B1 (pt)
MX (1) MXPA00007681A (pt)
MY (1) MY125921A (pt)
NO (2) NO329376B1 (pt)
NZ (1) NZ506389A (pt)
PE (1) PE20000272A1 (pt)
PL (1) PL201329B1 (pt)
PT (1) PT1052974E (pt)
RU (1) RU2214246C2 (pt)
SI (1) SI1052974T1 (pt)
SK (2) SK287775B6 (pt)
TR (1) TR200002299T2 (pt)
TW (1) TW457095B (pt)
WO (1) WO1999039694A2 (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
DE59610712D1 (de) 1995-11-17 2003-10-16 Biotechnolog Forschung Gmbh Epothilonderivate, herstellung und verwendung
CZ303422B6 (cs) 1996-11-18 2012-09-05 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilon C, zpusob jeho výroby a jeho použití jako cytostatik a prostredku pro ochranu rostlin
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
GB9802451D0 (en) * 1998-02-05 1998-04-01 Ciba Geigy Ag Organic compounds
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6303342B1 (en) 1998-11-20 2001-10-16 Kason Biosciences, Inc. Recombinant methods and materials for producing epothilones C and D
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
AU2002245296B2 (en) * 2001-01-25 2006-12-21 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
IL156580A0 (en) 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
ES2304240T3 (es) 2001-01-25 2008-10-01 Bristol-Myers Squibb Company Procedimientos para la preparacion de preparaciones farmaceuticas que contienen analogos de epotilona para el tratamiento de cancer.
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
BR0207487A (pt) 2001-02-20 2004-08-10 Brystol Myers Squibb Company Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
BR0207316A (pt) 2001-02-20 2004-02-10 Bristol Myers Squibb Co Derivados de epotilona para o tratamento de tumores refratários
RU2321400C2 (ru) 2001-03-14 2008-04-10 Бристол-Маерс Сквибб Компани Композиция аналога эпотилона в сочетании с химиотерапевтическими агентами для лечения рака
KR100863089B1 (ko) * 2001-03-19 2008-10-13 노파르티스 아게 지사제 및 에포틸론 또는 에포틸론 유도체를 포함하는혼합물
JP2004532888A (ja) 2001-06-01 2004-10-28 ブリストル−マイヤーズ スクイブ カンパニー エポチロン誘導体
AU2008203233B2 (en) * 2001-07-19 2010-04-29 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
CN1615136A (zh) 2002-01-14 2005-05-11 诺瓦提斯公司 包含埃坡霉素和抗代谢物的组合
WO2003077903A1 (en) 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
PL372070A1 (en) * 2002-06-10 2005-07-11 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
WO2003105828A1 (en) 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DK1506203T3 (da) 2002-08-23 2007-05-14 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoger deraf og anvendelser deraf
MXPA05003006A (es) 2002-09-23 2005-06-22 Squibb Bristol Myers Co Metodos para la preparacion, aislamiento y purificacion de epotilona b y estructuras cristalinas de rayos x y de epotilona b.
US7091193B2 (en) 2002-10-09 2006-08-15 Kosan Biosciences Incorporated Therapeutic formulations
SI1553938T1 (sl) * 2002-10-15 2007-06-30 Univ Louisiana State Uporaba epotilonskih derivatov za zdravljenje hiperparatiroidizma
AU2003291337B2 (en) 2002-11-07 2010-09-09 Kosan Biosciences Incorporated Trans-9,10-dehydroepothilone C and D, analogs thereof and methos of making the same
KR20060122819A (ko) * 2003-10-09 2006-11-30 코산 바이오사이언시즈, 인코포레이티드 치료학적 제형
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
KR20060127946A (ko) * 2004-01-29 2006-12-13 에자이 알앤드디 매니지먼트 가부시키가이샤 매크롤라이드계 화합물의 안정화 방법
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
CN100409846C (zh) * 2005-11-22 2008-08-13 菏泽睿鹰制药集团有限公司 一种埃坡霉素b脂质体制剂及应用
JP2010500387A (ja) 2006-08-16 2010-01-07 ノバルティス アクチエンゲゼルシャフト 結晶形態のエポチロンbおよび医薬組成物における使用
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
CN101642453B (zh) * 2009-09-15 2011-03-16 湖南迪诺制药有限公司 一种含有埃坡霉素b的药物制剂
GB201505347D0 (en) * 2015-03-27 2015-05-13 Salupont Consulting Ltd Sterilisation of s-nitrosothiols
JP7271517B2 (ja) * 2017-09-27 2023-05-11 ノバルティス アーゲー シポニモドを含む非経口製剤

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
IL27947A (en) * 1967-05-09 1972-07-26 Weitzman J Method for the production of thermoplastic resin particles and of mixtures of such particles with additives
JPS56115855A (en) * 1980-02-19 1981-09-11 Toyota Motor Corp Method and apparatus for controlling ignition timing of engine
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
US5216011A (en) * 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
DE4138042C2 (de) * 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
JPH0753396A (ja) * 1993-08-19 1995-02-28 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物,その製造法および用途
CA2092271C (en) * 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
HUT73844A (en) * 1994-11-11 1996-09-30 Chinoin Gyogyszer Es Vegyeszet New taxol complexes and pharmaceutical compositions containing them
JP3934705B2 (ja) * 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
DE59610712D1 (de) * 1995-11-17 2003-10-16 Biotechnolog Forschung Gmbh Epothilonderivate, herstellung und verwendung
CN101028259A (zh) * 1996-03-12 2007-09-05 Pg-Txl有限公司 水溶性紫杉醇产品
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
EP1386922B1 (en) * 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs

Also Published As

Publication number Publication date
US20060127423A1 (en) 2006-06-15
KR20010040534A (ko) 2001-05-15
KR100669174B1 (ko) 2007-01-17
BR9907647B1 (pt) 2014-04-01
CA2320182A1 (en) 1999-08-12
SK11702000A3 (sk) 2001-01-18
NO20003930L (no) 2000-10-04
CZ20002834A3 (cs) 2000-11-15
FR2774909B1 (fr) 2000-07-28
CL2003002786A1 (es) 2005-02-04
IL137550A (en) 2010-06-30
DE69940904D1 (de) 2009-07-02
SK287487B6 (sk) 2010-11-08
TR200002299T2 (tr) 2000-11-21
HUP0101564A2 (hu) 2001-11-28
FR2774909A1 (fr) 1999-08-20
NZ506389A (en) 2003-07-25
IT1313549B1 (it) 2002-09-09
CZ303168B6 (cs) 2012-05-09
CY1109311T1 (el) 2014-07-02
AR017979A1 (es) 2001-10-24
CN1292683A (zh) 2001-04-25
SK287775B6 (sk) 2011-09-05
HK1033809A1 (en) 2001-09-28
CN100396276C (zh) 2008-06-25
MXPA00007681A (es) 2003-07-14
WO1999039694A2 (en) 1999-08-12
US20070060627A1 (en) 2007-03-15
CN1623543A (zh) 2005-06-08
ES2324378T3 (es) 2009-08-05
US20080221065A1 (en) 2008-09-11
RU2214246C2 (ru) 2003-10-20
TW457095B (en) 2001-10-01
CA2320182C (en) 2008-11-25
PE20000272A1 (es) 2000-04-17
US20030203876A1 (en) 2003-10-30
NO329376B1 (no) 2010-10-04
PT1052974E (pt) 2009-08-07
HUP0101564A3 (en) 2002-06-28
PL201329B1 (pl) 2009-03-31
KR20080016756A (ko) 2008-02-21
ID26549A (id) 2001-01-18
BE1012140A3 (fr) 2000-05-02
MY125921A (en) 2006-08-30
AU753519B2 (en) 2002-10-17
NO20100302L (no) 2000-10-04
JP4644364B2 (ja) 2011-03-02
US20110124691A1 (en) 2011-05-26
AU2722699A (en) 1999-08-23
NO20003930D0 (no) 2000-08-03
SI1052974T1 (sl) 2009-10-31
IL137550A0 (en) 2001-07-24
WO1999039694A3 (en) 1999-09-23
JP2010090147A (ja) 2010-04-22
EP1052974A2 (en) 2000-11-22
CO4920246A1 (es) 2000-05-29
DK1052974T3 (da) 2009-08-10
KR20060002022A (ko) 2006-01-06
PL342629A1 (en) 2001-06-18
JP2002502810A (ja) 2002-01-29
ITMI990208A1 (it) 2000-08-04
ATE431733T1 (de) 2009-06-15
EP1052974B1 (en) 2009-05-20

Similar Documents

Publication Publication Date Title
BR9907647A (pt) Composições contendo composto orgânicos
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
BR0107147A (pt) Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações
BR0009564A (pt) Utilização de inibidores da cyp2d6 em terapias de combinação
SV1999000049A (es) Nuevas dihidropirimidinas 2 heterociclicamente sustituidas ref. lea 32793-sv
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
IT1309427B1 (it) Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell&#39;iperossaluria e suo uso
BR9810495A (pt) Composição farmacêutica
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BR9811458A (pt) &#34;sistema solvente para penetração melhorada de compostos farmacêuticos&#34;
ES2124477T3 (es) Uso de un fosfato de ascorbilo y tocoferilo para la preparacion de un medicamento para el tratamiento de la pancreatitis.
PA8496701A1 (es) Polimorfos de un diclorhidrato cristalino de azobiciclo [2.2.2] oct- 3 - ilamina y sus composiciones farmaceuticas
BR0011845A (pt) Complexo farmacêutico
IT1298442B1 (it) Composizioni orali a basso dosaggio di proteine citotossiche
PA8496001A1 (es) Polimorfos de un citrato de azobiciclo [2.2.2] oct-3-ilamina cristalino y sus composiciones farmaceuticas
BR9810387A (pt) (s) 3, 4, 5-trimetoxibenzoato de 2-metilamino-2-fenil-n-butila, e sua aplicação para o tratamento de dor crÈnica
DK1100463T3 (da) Injicerbare formuleringer indeholdende ramoplanin
BR0000011A (pt) Composições injetáveis de alatrofloxacina pré-mistruadas
BR0009113A (pt) Composição farmacêutica à base de compostospoliaromáticos
BRPI0412681A (pt) composição farmacêutica para a administração por via nasal de piribedil
DE60023307D1 (de) Phenanthrolin-7-onderivate und ihre therapeutische verwendung
DE69901721D1 (de) Pharmazeutische zusammensetzungen basierend auf alpha-cyclodextrin zur oralen verabreichung von lh-rh analogen
ECSP992852A (es) Compuestos organicos
GB9802451D0 (en) Organic compounds

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: APRESENTAR NA INTEGRA COPIA DAS DUAS PRIORIDADE REIVINDICADAS NO PEDIDO

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/04/2014, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2363 DE 19-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.